Journal: Journal of Translational Medicine

Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

doi: 10.1186/s12967-024-05099-6

Figure Lengend Snippet: AURKB interacts with and promotes the expression of MAD2L2. A Protein interaction network map of proteins bound to AURKB. B GO/KEGG enrichment analysis of AURKB in TCGA database. C GSEA results of AURKB in TCGA database. D Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. E Co-IP indicated the interaction between AURKB and MAD2L2 in BC cells. F T24 and 5637 cells were subjected to IF staining for AURKB (red) or MAD2L2 (green) and nuclei with DAPI (blue). G Representative IHC images of MAD2L2 in BC tissues and adjacent normal tissues. H The correlation analysis of AURKB and MAD2L2 H-score of IHC in patient samples. I The correlation analysis between AURKB and MAD2L2 expression in TCGA database. J Differential MAD2L2 expression in BC tissues and normal bladder tissues in unpaired and paired samples. K Kaplan–Meier survival curves for OS and DSS comparing the high and low expression of MAD2L2 in TCGA database. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

Techniques: Expressing, Western Blot, Co-Immunoprecipitation Assay, Staining, Microscopy

Journal: Journal of Translational Medicine

Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

doi: 10.1186/s12967-024-05099-6

Figure Lengend Snippet: AURKB ablation upregulates the p53 pathway and suppresses BC cell progression via MAD2L2. A - B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay demonstrated the capacity of migration. H The transwell assay demonstrated the capacity of invasion. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

Techniques: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Migration, Transwell Assay, Microscopy

Journal: Journal of Translational Medicine

Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

doi: 10.1186/s12967-024-05099-6

Figure Lengend Snippet: Ablation of MAD2L2 suppresses BC cell progression via p53 DDR pathway. A , B Cell growth was detected by CCK-8 assay ( A ) and colony-forming assay ( B ). C KI67 detection using IF staining. D Cell cycle analysis was measured by flow cytometry. E Representative images of SA-β-gal staining. F Western blot analysis of MAD2L2, CyclinD1, p53, p21 and γH2A.X expression. G The wound healing assay for T24 and 5637 cells. H The transwell assay for T24 and 5637 cells. (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

Techniques: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Wound Healing Assay, Transwell Assay, Microscopy

Journal: Journal of Translational Medicine

Article Title: AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

doi: 10.1186/s12967-024-05099-6

Figure Lengend Snippet: AURKB promotes BC growth and downregulats p53 DDR pahway by regulating MAD2L2 expression in vivo. A Images of dissected T24 xenograft tumors. B , C Tumor volume and weight in each group. D Representative images of IHC staining for MAD2L2, KI67, CyclinD1 and p53 in each group. E Western blot analysis of AURKB, MAD2L2, CyclinD1, p53, p21 and γH2A.X expression in each group (The magnification under the microscope is shown as marked in the figure. *p < 0.05, **p < 0.01)

Article Snippet: Antibodies used in IF were as follows: KI67 (1:200, 27309-1-AP, Proteintech, Wuhan, China), AURKB (1:50, A19539, ABclonal), MAD2L2 (1:50, A4630, ABclonal).

Techniques: Expressing, In Vivo, Immunohistochemistry, Western Blot, Microscopy

Journal: BMC Cancer

Article Title: Identification of a Novel CD8 + T cell exhaustion-related gene signature for predicting survival in hepatocellular carcinoma

doi: 10.1186/s12885-023-11648-x

Figure Lengend Snippet: Expression of STAM, ANXA5 and MAD2L2 in HCC cell lines. A The expressions of STAM, ANXA5 and MAD2L2 in normal hepatocytes and hepatoma cell lines were detected using Western blotting. Knocking down STAM, ANXA5 and MAD2L2 inhibited the proliferation and migration of HCC cells. B The knockdown efficiency of STAM, ANXA5 and MAD2L2 was detected using Western Blotting. C Plate cloning experiment showed that the number of cloned cell clusters formed by hepatocellular carcinoma cells after knockdown of STAM, ANXA5 and MAD2L2 was significantly reduced; D The results of CCK8 experiment showed that inhibiting the expression of STAM, ANXA5 and MAD2L2 decreased the proliferative ability of HCC cells; E Scratch assay showed that knockdown of STAM, ANXA5 and MAD2L2 inhibited the migration of hepatocellular carcinoma cells; F Transwell experiment showed that the migration ability of hepatocellular carcinoma cells was weakened after inhibiting the expression of STAM, ANXA5 and MAD2L2 .* P < 0.05, ** P < 0.01, *** P < 0.001, there was no significant difference in ns

Article Snippet: Anti- MAD2L2 (BM5428) and anti- STAM (A00864-1) antibodies were purchased from BosterBio (Pleasanton, CA, USA), while Anti- TBL1XR1 (MBS850368), Anti- ANXA5 (MBS474163), Anti- FKBP1A (MBS9404059) and Anti- PPM1G (MBS626576) antibodies were purchased from MyBioSource (San Diego, CA, USA).

Techniques: Expressing, Western Blot, Migration, Knockdown, Cloning, Clone Assay, Wound Healing Assay

Journal: Cell

Article Title: Repair of a DNA-protein crosslink by replication-coupled proteolysis

doi: 10.1016/j.cell.2014.09.024

Figure Lengend Snippet: (A) Mock-depleted and Rev7-depleted egg extracts were blotted with Rev7 and MCM7 antibodies. (B) The extracts from (A) were used for replication of pDPCBot as in Figure 1B (+ProtK). (C) Samples from (B) were analyzed as in Figure 2C.

Article Snippet: Antibodies The following antibodies were described previously: FANCD2 ( Räschle et al., 2008 ), MCM7 ( Walter and Newport, 2000 ), Rev7 ( Räschle et al., 2008 ) and CDT1 ( Arias and Walter, 2005 ). p-Chk1 (S345) and ubiquitin antibodies were purchased from Cell Signaling (#2341) (Danvers, MA, USA) and Santa Cruz (SC-8017), respectively.

Techniques: